Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey

INTRODUCTION: Were the participants of the EMPA-REG OUTCOME trial representative of patients receiving empagliflozin in clinical practice? The aim of the present study was to examine the prevalence of cardiovascular disease (CVD) in type 2 diabetes patients starting empagliflozin treatment in routin...

Descripción completa

Detalles Bibliográficos
Autores principales: Eliasson, Björn, Ekelund, Jan, Amberntsson, Rikard, Miftaraj, Mervete, Svensson, Ann-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612325/
https://www.ncbi.nlm.nih.gov/pubmed/31089969
http://dx.doi.org/10.1007/s13300-019-0632-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612325/
https://www.ncbi.nlm.nih.gov/pubmed/31089969
http://dx.doi.org/10.1007/s13300-019-0632-4

Ejemplares similares